- Oral BG-12 in relapsing-remitting MS2009 | First Faculty of Medicine
- Oral BG-12 in Multiple Sclerosis Reply2013 | First Faculty of Medicine
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis2011 | Second Faculty of Medicine
- Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM2013 | First Faculty of Medicine
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | Second Faculty of Medicine
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study2013 | First Faculty of Medicine
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis2011 | First Faculty of Medicine
- Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study2014 | First Faculty of Medicine
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | First Faculty of Medicine
- Dimethyl-fumarate in treating relapsing-remitting multiple sclerosis2014 | Second Faculty of Medicine
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis2012 | First Faculty of Medicine
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis2012 | Second Faculty of Medicine
- Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison2014 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | First Faculty of Medicine
- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis2019 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | First Faculty of Medicine
- Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a2021 | First Faculty of Medicine
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study2015 | First Faculty of Medicine